laboratory study suggests therefore, that further experimental and clinical evaluation of hypnotics in common use, whether barbiturates or not, is urgently required.

We are grateful to our subjects; to Roche (Products) Limited, who kindly provided, through Dr. M. Duffus, the placebo and active treatments as well as generous financial support to one of us (A.M.); and to Miss S. Virdian and D. Navsa for help with the E.E.G. recordings.

REFERENCES

- Cochran, W. G., and Cox, G. M. (1957). *Experimental Designs*. London, Chapman and Hall.
- Crossman, E. R. F. W. (1953). *Quarterly Journal of Experimental Psychology*, **5**, 41.
- Davies, C., and Levine, S. (1967). *British Journal of Psychiatry*, **113**, 1005.
- Ditt, J. (1964). Congress of the German Society of Forensic and Social Medicine, Zurich, 17 October.
- Doenicke, A., Kugler, J., Schellenberger, A., and Gürtner, T. (1966). *British Journal of Anaesthesia*, **38**, 580.
- Goodnow, R. E., Beecher, H. K., Brazier, M. A. B., Mosteller, F., and Tagiuri, R. (1951). *Journal of Pharmacology and Experimental Therapeutics*, **102**, 55.
- Haider, I. (1968). *British Journal of Psychiatry*, **114**, 337.
- Harrer, G. (1965). *Progress in Brain Research*, **18**, 228.
- Kornetsky, C., Vates, T. S., and Kessler, E. K. (1959). *Journal of Pharmacology and Experimental Therapeutics*, **127**, 51.
- Malpas, A., and Joyce, C. R. B. (1969). *Psychopharmacologia*, **14**, 167.
- Matthew, H., Proudfoot, A. T., Aitken, R. C. B., Raeburn, J. A., and Wright, N. (1969). *British Medical Journal*, **3**, 223.
- Morgan, H., Scott, D. F., and Joyce, C. R. B. (1970). *British Journal of Psychiatry*. In press.
- Oswald, I., and Priest, R. G. (1965). *British Medical Journal*, **2**, 1093.
- Prior, P. F., and Deacon, P. A. (1969). *Electroencephalography and Clinical Neurophysiology*, **27**, 422.
- Reynolds, E., Joyce, C. R. B., Swift, J. L., Tooley, P. H., and Weatherall, M. (1965). *British Journal of Psychiatry*, **111**, 84.
- Volavka, J. V., et al. (1969). *Psychopharmacologia*, **14**, 178.
- Wyss, S., and Mäder, A. (1965). *Schweizerische medizinische Wochenschrift*, **95**, 338.

Long-term and Short-term Effects of Oral Prethcamide in Chronic Ventilatory Failure

R. A. L. BREWIS,* M.D., ; M.R.C.P. N. G. HODGES,† M.B., B.CH., M.R.C.P.

British Medical Journal, 1970, **2**, 764-766

Summary: The effect of oral prethcamide (Micoren) (a mixture of two related amides of crotonyl N' butyric acid) was compared with a placebo preparation in 13 patients with established chronic ventilatory failure. Part I of the study comprised a double-blind single cross-over trial with an initial assessment and two further assessments at the end of each period of one month. Prethcamide was taken in 200-mg. doses four times daily. No subjective or objective changes were noted, and in particular the resting PCO_2 showed no change.

Part II of the study comprised a double-blind single cross-over trial of the short-term effect of prethcamide compared with placebo in 12 patients in chronic ventilatory failure. Frequent estimations of mixed venous PCO_2 were made with a rebreathing technique for four and a half hours after ingestion of prethcamide or placebo preparation.

Following prethcamide a fall in PCO_2 level to a minimum value at 30 minutes of 93% of control values and persisting for about three hours was noted for the group as a whole. The fall represents a lowering by about 4 mm. Hg of the mixed venous PCO_2 .

It is concluded that, though in patients with chronic ventilatory failure prethcamide may reduce the PCO_2 in the short term, there is no subjective benefit or observable objective change following repeated administrations over a period of one month.

Introduction

Patients with obstructive airways disease who develop chronic ventilatory failure commonly have a less severe degree of air-

ways obstruction than some other patients who are, nevertheless able to maintain a normal arterial PCO_2 . While there may be differences of lung morphology in these two groups, there is strong evidence that some patients with chronic hypoventilation have a defective central drive to breathe, and voluntary overbreathing in these individuals results in a lowering of the arterial PCO_2 and an increase in PO_2 . In these patients stimulation of ventilation might prove beneficial. Respiratory stimulants such as nikethamide have found some place in the management of acute respiratory failure accompanying acute exacerbations of chronic obstructive airways disease (Lancet, 1963). Prethcamide (Micoren), a mixture of two related amides of crotonyl N' butyric acid, has been shown to stimulate respiration in the short term (Domenet and Kennedy, 1967) and has been used in the acute situation, but no controlled trial of the long-term use of this drug, orally, in patients with established chronic ventilatory failure has been reported to date.

Patients and Methods

Part I. Long Term

Sixteen patients with chronic ventilatory failure attending the respiratory clinic at Manchester Royal Infirmary were admitted to the trial. In every case the three previous estimations of the arterial PCO_2 were in excess of 44 mm. Hg and extended over a period of at least three months before the beginning of the trial. The study took the form of a double-blind comparison of prethcamide and placebo, each administered for four weeks. All patients had an initial assessment, and a further assessment at the end of each period. Prethcamide was prescribed in the form of capsules, each containing 200 mg., and a dose of 400 mg. was taken four times daily. The patients were provided with typewritten information about the trial and specifically urged to continue taking the capsules up to and including the morning of the next assessment. The placebo preparation was identical in appearance.

* Lecturer in Medicine, University of Manchester. At present Senior Lecturer in Medicine, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP.

† Research Fellow, United Manchester Hospitals. At present Registrar in Medicine, Southampton General Hospital, Southampton.

The study took place over the spring of 1969, and to guard against any possible effect of seasonal improvement patients were admitted in groups of four in which two had placebo in the first period and two the active preparation, the allocation being otherwise random.

At each assessment the patient was asked to score breathlessness, exercise tolerance, and cough, by making, for each, a mark on a 10-cm. line marked "perfect" at one end and "terrible" at the other. The distance in mm. from the mark to the "terrible" end of the line was subsequently measured. The patient was asked whether the preceding month had been better, the same, or worse than the month before that. Work loss, exacerbations, changes in therapy, and side-effects were also noted. The time at which the morning dose had been taken was also recorded. The arterial PCO_2 was estimated from the mixed venous PCO_2 by the rebreathing technique of Campbell and Howell (1962). The PCO_2 was measured after resting seated for 15 minutes and again after a further 15 minutes. If the two results differed by more than 2 mm. Hg a third reading was taken after a further 15 minutes. Duplicate analyses were performed on each bag and a mean of all the readings taken was recorded. For convenience this mixed venous PCO_2 was converted to an "arterial" PCO_2 by subtracting 9 mm. Hg. A reproducible forced expiratory spiogram was obtained with a Vitalograph, and F.E.V.₁ and forced vital capacity were measured.

Analysis of Results.—The difference between the results at control, placebo, and prethcamide assessments were calculated, and for each assessment the mean and standard deviation was calculated for the group as a whole for each of the three assessments. For each patient the differences between the values obtained at each assessment were calculated and the differences between the prethcamide, placebo, and control assessments subjected to Student's *t* test.

Part II. Short Term

Eleven of the 13 patients who completed part I of the trial and one who did not complete it took part in a double-blind controlled trial designed to assess the immediate effects of a single oral dose of prethcamide. None had received the drug for at least three weeks previously. On two mornings, two days apart, the patients, after a light breakfast, attended the respiratory department. After they had rested for 10 minutes three estimations of the arterial PCO_2 by the rebreathing technique were made at 15-minute intervals. A dose of 400 mg. of prethcamide or an identical placebo preparation was then administered orally. PCO_2 estimations continued at 15-minute intervals for one hour and then at half-hourly intervals until two and a half hours after the dose, when a light sandwich lunch was taken. After a 15-minute interval estimations continued at half-hourly intervals until four and a quarter hours from the time of taking the dose. The CO_2 concentration of the rebreathing bags was measured from the recorded tracing from a Grubb Parsons CO_2 analyser frequently calibrated with three standard CO_2/O_2 mixtures spanning the range used. An "arterial" PCO_2 was derived from the mixed venous PCO_2 as in part I of the trial.

Analysis of Results.—The mean of the three control PCO_2 values was calculated. Subsequent PCO_2 estimations were expressed as a percentage of this value. The results for the group as a whole were expressed by calculating the mean value and standard error for each period after the dose for each of the two days. Individual responses were assessed by subtracting active from placebo mean percentage drugs from control values for each period after the dose. The significance of the variation of these differences from zero was then assessed with Student's *t* test.

Results

Part I. Long Term

Of 16 patients admitted to the trial three were subsequently withdrawn. One was admitted to hospital and died in acute respiratory failure soon after the trial was begun. One patient developed gastrointestinal symptoms on both active and placebo preparations and was taking neither at the time of the assessments. The third patient tolerated the placebo preparation and showed no subjective or objective change but developed increased breathlessness after each dose of the active preparation and ceased taking it. The results reported refer to the remaining 13 patients and are summarized in Tables I and II.

TABLE I.—Derived "Arterial" PCO_2 (mm. Hg) at the Three Assessments of Part I of the Trial (Long Term)

Case No.	Control	Placebo	Prethcamide
1	57	55.5	52.5
2	57.5	60.5	68
3	55	60.5	62
4	63.5	69	59.5
5	51	48	47.5
6	59	68.5	67.5
7	58	77	76
8	48	43	43
9	53	51	54
10	51	48	49
11	53	47.5	51
12	52	51.5	57.5
13	52.5	66.5	68
Mean (S.D.)	54.7 (4.2)	57.4 (10.4)	58.1 (9.8)

TABLE II.—Summary of Results of Part I of the Trial (Long Term)

	No.	Control	Placebo	Prethcamide
		Mean (S.D.)	Mean (S.D.)	Mean (S.D.)
PCO_2 (mm. Hg)	13	54.7 (4.2)	57.4 (10.4)	58.1 (9.8)
F.E.V. ₁ (l.)	13	0.83 (0.22)	0.83 (0.27)	0.84 (0.23)
V.C. (l.)	13	2.16 (0.85)	2.00 (0.63)	2.14 (0.77)
Exercise tolerance score*	12	4.77 (2.03)	5.89 (1.78)	5.48 (1.73)
Dyspnoea score*	11	4.83 (1.58)	5.25 (1.54)	4.66 (2.17)
Cough*	12	6.57 (2.01)	5.96 (1.90)	6.23 (2.78)

*Derived from the patient marking a 10-cm. line: 0 = terrible 10 = perfect, in each case.

The mean PCO_2 after taking prethcamide for a month was slightly higher than the mean level after the control period or at the initial assessment. Only three patients had a lower PCO_2 after taking prethcamide than at the other two assessments. Analysis of the results showed that the PCO_2 levels at the three assessments were not significantly different. There was no significant change in the F.E.V.₁ or V.C. at the various assessments. The patients' own scores for exercise tolerance, breathlessness, and cough similarly showed no significant change. The patients' overall assessment of each month compared with the month before is shown in Table III. No preference for either prethcamide or placebo emerged.

TABLE III.—Part I of the Trial (Long Term). Patients' Own Assessment of the Month Past Compared with the Month Before That

		Control Assessment			End of First Period			End of Second Period		
		W	S	B	W	S	B	W	S	B
Placebo first. No. of patients	..	Placebo			Prethcamide					
	..	3	2	1	2	1	3	2	1	3
Prethcamide first. No. of patients	..	Prethcamide			Placebo					
	..	2	2	3	2	2	3	2	2	3

B = Better S = Same W = Worse

Part II. Short Term

The mean resting PCO_2 for the group as a whole was 61 mm. Hg and the effect of a single oral dose of prethcamide is shown in the Chart. A fall in PCO_2 after prethcamide reaching

a minimum at 30 minutes and lasting for three hours is shown. Thirty minutes after the oral dose the mean PCO_2 for the group as a whole was 93.3% of the control value. This represents an average fall of just over 4 mm. Hg. Analysis of the individual responses (Table IV) shows that 5 of the 12

TABLE IV.—Part II of the Trial (Short Term). Mean Difference over Four and a Half Hours in Changes from Control PCO_2 Values (— indicates PCO_2 Less on Prethcamide)

Case No.	Mean Difference (%)	S.D.	P
1	-6.11	3.18	0.001
4	-9.76	5.78	<0.002
5	-2.24	3.85	N.S.
6	2.8	7.85	N.S.
8	0.48	3.39	N.S.
9	-3.05	4.71	0.1-0.05
10	-4.90	6.70	<0.05
11	2.47	4.92	N.S.
12	-6.66	4.69	0.002
13	-2.26	3.18	0.1-0.05
15	-2.20	6.16	N.S.
16	-4.50	2.677	<0.001

PaCO_2 expressed as a percentage of the control values after a single oral dose of prethcamide 400 mg. or placebo.

patients had a significant difference between the two assessments and in all five the lower PCO_2 values were obtained on prethcamide. A further four patients showed lower PCO_2 levels after prethcamide than after placebo, but the difference was not significant.

Discussion

The results presented reaffirm the respiratory stimulant effect of prethcamide and show that patients with chronic obstructive airways disease and chronic ventilatory failure can be induced to increase their resting alveolar ventilation slightly with an oral dose of 400 mg. It seems reasonable,

to assume that neither change in cardiac output nor CO_2 production is responsible for the observed lowering of PCO_2 . We have not been able to demonstrate any objective or subjective response to regular consumption of prethcamide. The possible explanations for the failure to observe lowering of the PCO_2 on long-term treatment are: (1) the patients failed to take the drug, (2) the effect of the morning dose had passed before they were observed, (3) tolerance to the drug developed, and (4) the variations in resting PCO_2 between visits one month apart were large enough to mask the small effect of the drug.

We believe that failure to take the drug regularly is unlikely to be the explanation in this particular group of patients, who were extremely co-operative (as the excellent attendances for part II of the trial show). They were explicitly asked to take the dose as usual on the morning of the assessments, and the assessments were almost all performed between one and a half and three and a half hours after the morning dose had been taken. The peak effect noted during the short-term trial occurred at 30 minutes, but a lowering was still present at three hours. We believe that failure to find any effect after long-term administration of prethcamide is due to the development of tolerance, to the weak effect of the drug being masked by the wide variations in PCO_2 , or to both those factors.

Boulet *et al.* (1963) noted a fall of about 10 mm. Hg. from pretreatment arterial PCO_2 levels persisting 24 hours after the completion of a 15-day open trial of a twice-daily oral dose of 375 mg. of prethcamide. The fall in PCO_2 was found in every patient. Only 3 of the 12 patients studied had an arterial PCO_2 level in excess of 46 mm. Hg. There is no obvious explanation for the discrepancy between this result and that of the present study. Our failure to find any improvement in the vital capacity or to find any subjective improvement is in contrast to the report by Germouty and Jault (1965).

On the basis of a one-month trial we find nothing to support the long-term administration of this drug to patients with obstructive airways disease and chronic ventilatory failure, and doubt whether the short-term response we have found is large enough to be clinically worth while. We would emphasize that none of the patients were studied during an acute exacerbation. Possibly the drug has some place in this context and in combating the fall in ventilation which may accompany oxygen therapy.

We are grateful to Dr. J. G. Domenet, of Geigy (U.K.) Limited, for supplies of Micoren and to Professor J. B. L. Howell for advice and permission to study patients under his care. One of us (N. G. H.) was in receipt of a research fellowship from United Manchester Hospitals.

REFERENCES

- Boulet, P., Barjon, P., and Fabre, S. (1963). *Semaine Thérapeutique*, **39**, 127.
- Campbell, E. J. M., and Howell, J. B. L. (1962). *British Medical Journal*, **2**, 630.
- Domenet, J. G., and Kennedy, M. C. S. (1967). *British Journal of Diseases of the Chest*, **61**, 25.
- Germouty, J., and Jault, D. (1965). *Progrès Médical (Paris)*, **93**, 357.
- Lancet*, 1963, **2**, 344.